表紙
市場調査レポート

オピオイド誘発性便秘 - パイプライン分析

Opioid-Induced Constipation (OIC) - Pipeline Review, H1 2016

発行 Global Markets Direct 商品コード 257786
出版日 ページ情報 英文 70 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.39円で換算しております。
Back to Top
オピオイド誘発性便秘 - パイプライン分析 Opioid-Induced Constipation (OIC) - Pipeline Review, H1 2016
出版日: 2016年02月24日 ページ情報: 英文 70 Pages
概要

オピオイドは効果的な鎮痛剤ですがが、しばしば便秘の副作用があります。これらの薬は、様々な形で消化器管に影響を及ぼします。例えば、オピオイドによって便が消化器官を移動するのに時間がかかってしまいます。小腸(空腸)の真ん中で非推進収縮を起こし、縦の推進力である蠕動運動を抑制します。その結果、食物は消化管の中を移動できなくなります。オピオイドによって部分的に胃が麻痺(胃不全麻痺)するため、食物が長時間、消化器の中に残ってしまいます。その上、オピオイドは消化液の分泌を減らし、便意を抑えてしまいます。 オピオイド誘発性便秘の症状は、気分が悪くなり、吐き気をもよおし、疲労、無気力、食欲不振を感じ、気分が落ち込むこともあります。

当レポートでは、オピオイド誘発性便秘の治療薬開発パイプラインの現況と最新アップデートによる各開発段階の比較分析、企業や研究機関によって開発中の治療薬、治療薬の評価、後期段階および中止されたプロジェクトに関する情報などを最新のニュースや発表も交えて提供しています。

イントロダクション

  • 調査範囲

オピオイド誘発性便秘 概要

治療薬の開発

  • パイプライン製品;概要
  • パイプライン製品;比較分析

企業で開発中の治療薬

パイプライン製品の概況

  • 後期段階の製品
  • 臨床段階の製品

企業で開発中の製品

治療薬開発に従事している企業

  • AstraZeneca PLC
  • Cosmo Pharmaceuticals S.p.A
  • Cubist Pharmaceuticals, Inc.
  • Develco Pharma Schweiz AG
  • Ironwood Pharmaceuticals, Inc.
  • S.L.A. Pharma AG
  • Salix Pharmaceuticals Ltd.
  • 塩野義製薬
  • Sucampo Pharmaceuticals, Inc.
  • Synergy Pharmaceuticals, Inc.

治療薬の評価

  • 単剤製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

  • axelopran
  • bevenopran
  • linaclotide
  • lubiprostone
  • methylnaltrexone bromide
  • naldemedine
  • naloxegol oxalate
  • naloxone hydrochloride
  • naloxone hydrochloride PR
  • naloxone hydrochloride SR
  • SP-333

最近のパイプライン動向

休止中のプロジェクト

開発が中止された製品

製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC7669IDB

Summary

Global Markets Direct's, 'Opioid-Induced Constipation (OIC) - Pipeline Review, H1 2016', provides an overview of the Opioid-Induced Constipation (OIC) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Opioid-Induced Constipation (OIC), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Opioid-Induced Constipation (OIC) and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Opioid-Induced Constipation (OIC)
  • The report reviews pipeline therapeutics for Opioid-Induced Constipation (OIC) by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Opioid-Induced Constipation (OIC) therapeutics and enlists all their major and minor projects
  • The report assesses Opioid-Induced Constipation (OIC) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Opioid-Induced Constipation (OIC)

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Opioid-Induced Constipation (OIC)
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Opioid-Induced Constipation (OIC) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Opioid-Induced Constipation (OIC) Overview
  • Therapeutics Development
    • Pipeline Products for Opioid-Induced Constipation (OIC) - Overview
  • Opioid-Induced Constipation (OIC) - Therapeutics under Development by Companies
  • Opioid-Induced Constipation (OIC) - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
  • Opioid-Induced Constipation (OIC) - Products under Development by Companies
  • Opioid-Induced Constipation (OIC) - Companies Involved in Therapeutics Development
    • Ironwood Pharmaceuticals, Inc.
    • Shionogi & Co., Ltd.
    • Sucampo Pharmaceuticals, Inc.
    • Synergy Pharmaceuticals, Inc.
    • Theravance Biopharma, Inc.
    • Valeant Pharmaceuticals International, Inc.
  • Opioid-Induced Constipation (OIC) - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • (axelopran sulfate + oxycodone hydrochloride) - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • axelopran sulfate - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • dolcanatide - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • linaclotide - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • lubiprostone - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • methylnaltrexone bromide - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • methylnaltrexone bromide - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • naldemedine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Opioid-Induced Constipation (OIC) - Recent Pipeline Updates
  • Opioid-Induced Constipation (OIC) - Dormant Projects
  • Opioid-Induced Constipation (OIC) - Discontinued Products
  • Opioid-Induced Constipation (OIC) - Product Development Milestones
    • Featured News & Press Releases
      • Nov 30, 2015: Ironwood Reports Positive Top-Line Data from Phase II Trial of Linaclotide in Adult Patients With Opioid-Induced Constipation
      • Sep 10, 2015: Theravance Biopharma Presents Positive Clinical Data on Fixed-Dose Combination (FDC) of Axelopran (TD-1211) and Oxycodone at PAINWeek 2015
      • Sep 08, 2015: Valeant And Progenics Announce FDA Acceptance Of NDA Submission For Oral RELISTOR
      • Aug 03, 2015: Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation
      • Jun 24, 2015: Shionogi Announces That Naldemedine Met The Primary Endpoint In Its First Japanese Phase 3 Study For The Treatment Of Opioid - Induced Constipation In Cancer Patients
      • Jun 03, 2015: RELISTOR Receives European Approval for Expanded Indication to Treat All Opioid-Induced Constipation
      • May 19, 2015: Phase IIb Data Show Once-Daily Naldemedine Provides Significant Improvement For Patients With Opioid-Induced Constipation
      • May 15, 2015: Sucampo Announces Clinical Data on Lubiprostone to be Presented at Digestive Disease Week
      • Apr 24, 2015: RELISTOR Receives Positive CHMP Opinion in the EU for the Treatment of Opioid-Induced Constipation in Adults with Chronic Non-Cancer Pain
      • Mar 30, 2015: Shionogi Announces That Naldemedine Meets Primary Endpoint In A Phase 3 Study For The Treatment Of Opioid-Induced Constipation
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Opioid-Induced Constipation (OIC), H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Opioid-Induced Constipation (OIC) - Pipeline by Ironwood Pharmaceuticals, Inc., H1 2016
  • Opioid-Induced Constipation (OIC) - Pipeline by Shionogi & Co., Ltd., H1 2016
  • Opioid-Induced Constipation (OIC) - Pipeline by Sucampo Pharmaceuticals, Inc., H1 2016
  • Opioid-Induced Constipation (OIC) - Pipeline by Synergy Pharmaceuticals, Inc., H1 2016
  • Opioid-Induced Constipation (OIC) - Pipeline by Theravance Biopharma, Inc., H1 2016
  • Opioid-Induced Constipation (OIC) - Pipeline by Valeant Pharmaceuticals International, Inc., H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Assessment by Combination Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Opioid-Induced Constipation (OIC) Therapeutics - Recent Pipeline Updates, H1 2016
  • Opioid-Induced Constipation (OIC) - Dormant Projects, H1 2016
  • Opioid-Induced Constipation (OIC) - Discontinued Products, H1 2016

List of Figures

  • Number of Products under Development for Opioid-Induced Constipation (OIC), H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Targets, H1 2016
  • Number of Products by Stage and Targets, H1 2016
  • Number of Products by Mechanism of Actions, H1 2016
  • Number of Products by Stage and Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Types, H1 2016
Back to Top